Call Us Now: +1 (706) 549-4484

  • Home
  • Company
    • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Advisors
    • News/Media
    • Careers
    • Contact Us
  • Technology
    • Overview
    • Lectenz® Platform
    • GlycoSenseTM Platform
  • Products
    • Lectenz®
      • Sialic Acid Lectenz® Products
      • N-Glycan Lectenz® Products
    • GlycoSenseTM
      • GlycoSenseTM glycoenzyme reaction monitoring kits
      • GlycoSenseTM bioprocess monitoring kits
  • Services
  • Investors
    • Market Opportunity
    • Financing and Revenue
    • Awards, Honors, and Recognitions
    • Intellectual Property Portfolio

Lectenz® Bio receives NIH SBIR Phase I

HomeAll postsLectenz® Bio NewsLectenz® Bio receives NIH SBIR Phase I
Lectenz® Bio receives NIH SBIR Phase I
by lectenz® Bio September 1, 2017 in Lectenz® Bio News 0 0

The National Institute of General Medical Sciences (NIGMS) awards Lectenz® Bio a second SBIR Phase I to apply the GlycoSenseTM technology to monitoring glycoenzyme engineering reactions.

Tweets by @glycosensors
Press Inquiries
Press Inquiries
Contact Info
  111 Riverbend Road
      Athens, GA 30602
      U.S.A.
+1 (706) 549-4484
+1 (706) 353-8485
      Contact Us
recent post
Lectenz® Bio receives patent issuance from USPTO
Lectenz® Bio receives patent issuance from USPTO
14 days ago
Lectenz® Bio receives NIH SBIR Phase II
Lectenz® Bio receives NIH SBIR Phase II
January 15, 2018
About Us
Lectenz® Bio is commercializing enabling technologies for applications in glycoscience and delivering tools that advance research and clinical applications.
Website By: JH Media Group: Healthcare & Diagnostic Imaging Website Design & Lead Generation